title: Inhibition of recombinant human cardiac L-type Ca2+ channel alpha1C subunits by 3-isobutyl-1-methylxanthine.
abstract: Inhibition of ion channels by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) and related compounds has been demonstrated in various cell types, including the neuromuscular junction, GH3 cells and vascular smooth muscle cells. These effects may be unrelated to the actions of these compounds on cellular metabolism, intracellular Ca2+ stores and phosphodiesterase inhibition. In this study, the inhibition of recombinant human cardiac L-type Ca2+ channel alpha1C subunits by IBMX was examined using the whole-cell configuration of the patch clamp technique. Inhibition was repeatable, voltage-independent and associated with increased apparent channel inactivation. The actions of IBMX were unaffected in the presence of inhibitors of protein kinases A and G. The non-xanthine phosphodiesterase inhibitor rolipram had a small inhibitory effect on currents, but this was also unaffected by a protein kinase A inhibitor. These effects of IBMX could not be attributed to release of Ca2+ from intracellular stores. Our findings indicate that methylxanthines can inhibit the cardiac L-type Ca2+ channel alpha1C subunit in the absence of auxiliary subunits by an undetermined, possibly direct mechanism.
authors.affiliation: Institute for Cardiovascular Research, University of Leeds, UK.
authors.forename: I M
authors.initials: IM
authors.lastname: Fearon
authors.forename: A C
authors.initials: AC
authors.lastname: Palmer
authors.forename: A J
authors.initials: AJ
authors.lastname: Balmforth
authors.forename: S G
authors.initials: SG
authors.lastname: Ball
authors.forename: G
authors.initials: G
authors.lastname: Mikala
authors.forename: C
authors.initials: C
authors.lastname: Peers
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology*; D000241:Adenosine / Q000037:antagonists & inhibitors; D001464:Barium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000235:genetics / Q000378:metabolism*; D002999:Clone Cells; D005415:Flavins / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006801:Humans; D008564:Membrane Potentials / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D005415:Flavins; D010726:Phosphodiesterase Inhibitors; D011994:Recombinant Proteins; D001464:Barium; C008173:isoalloxazine; D000241:Adenosine; D015056:1-Methyl-3-isobutylxanthine